

AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

1-47. (Cancelled).

48. (New) A packaged pharmaceutical composition comprising:


(a) a pharmaceutical composition comprising:

(i) a compound of the formula:



or a pharmaceutically acceptable salt thereof wherein:

Q represents a group of the Formula:



wherein A is C₁-C₅ alkylene optionally mono-, di, or trisubstituted with substituents independently chosen from C₁-C₃ alkyl, C₁-C₃ alkoxy, halogen, halo(C₁-C₃)alkyl, halo(C₁-C₃)alkoxy, hydroxy, amino, and mono- or di(C₁-C₃)alkylamino;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ are the same or different and independently represent hydrogen, halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkyl amino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxy carbonyl, -COOH, -SO₂NH₂, mono or dialkylsulfonamido, -C(O)NH₂, or mono or di(C₁-C₆)alkylcarboxamido;

R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ independently represent hydrogen or C₁-C₆ alkyl;

W is nitrogen or C-R_a where R_a represents hydrogen, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl or cyano;

X represents halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkylamino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxycarbonyl, -COOH, -CONH₂, mono- or di(C₁-C₆)alkylcarboxamido, -SO₂NH₂, mono or di(C₁-C₆)alkylsulfonamido; or

X represents phenyl which may be optionally substituted by up to five substituents, which may be the same or different and are selected from the group consisting of hydrogen, halogen, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, hydroxy, amino, mono or di(C₁-C₆)alkyl amino, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, C₁-C₆ alkanoyl, C₁-C₆ alkoxycarbonyl, -COOH, -CONH₂, mono- or di-(C₁-C₆)alkylcarboxamido, -SO₂NH₂, and mono or di(C₁-C₆)alkylsulfonamido;

Y is oxygen, sulfur, -S(O)-, or -SO₂-; and

Z is C₁-C₆ alkyl or mono, di or trifluoromethyl; and

(ii) at least one pharmaceutically acceptable carrier or excipient; and

(b) instructions for using the composition to treat a patient suffering from an eating disorder or sexual disorder.

49. (New) A packaged pharmaceutical composition according to claim 48, wherein the patient is suffering from an eating disorder.

50. (New) A packaged pharmaceutical composition according to claim 49, wherein the eating disorder is obesity.


51. (New) A packaged pharmaceutical composition according to claim 49, wherein the eating disorder is bulimia.

52. (New) A packaged pharmaceutical composition according to claim 48, wherein the patient is suffering from a sexual disorder.

53. (New) A packaged pharmaceutical composition according to claim 52, wherein the sexual disorder is anorgasmic or psychogenic impotence.

54. (New) A packaged pharmaceutical composition according to claim 48, wherein the instructions are provided as labeling on a container holding the compound and the at least one pharmaceutically acceptable carrier or excipient.

55. (New) A packaged pharmaceutical composition according to claim 48, wherein Q is a group of the Formula:



and A is methylene optionally substituted with C₁-C₂ alkyl.

56. (New) A packaged pharmaceutical composition according to claim 55, wherein A is methylene and W is nitrogen.

57. (New) A packaged pharmaceutical composition according to claim 56, wherein R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈ and R₁₉ are hydrogen.

58. (New) A packaged pharmaceutical composition according to claim 57, wherein:

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is halogen or phenyl;

Y is oxygen; and

Z is C₁-C₆ alkyl.

59. (New) A packaged pharmaceutical composition according to claim 55, wherein A is methylene and W is CH.

60. (New) A packaged pharmaceutical composition according to claim 59, wherein R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈ and R₁₉ are hydrogen.

61. (New) A packaged pharmaceutical composition according to claim 60, wherein:


R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is halogen or phenyl;

Y is oxygen; and


Z is C₁-C₆ alkyl.

62. (New) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



wherein A is methylene optionally substituted with C₁-C₂ alkyl.

63. (New) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



64. (New) A packaged pharmaceutical composition according to claim 63, wherein R₁₃, R₁₅, R₁₇ and R₁₉ are hydrogen;

R₁₀, R₁₁, R₁₂, R₁₄, R₁₆ and R₁₈ independently represent hydrogen or methyl;

W is N or CH;


R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ independently represent hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is hydrogen or halogen;

Y is oxygen; and

Z is C₁-C₆ alkyl.

65. (New) A packaged pharmaceutical composition according to claim 48, wherein the compound has the formula:



66. (New) A packaged pharmaceutical composition according to claim 65, wherein R₁₃, R₁₅, R₁₇ and R₁₉ are hydrogen;

R₁₀, R₁₁, R₁₂, R₁₄, R₁₆ and R₁₈ independently represent hydrogen or methyl;

W is N or CH;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ independently represent hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or trifluoromethoxy;

X is hydrogen or halogen;

Y is oxygen; and

Z is C₁-C₆ alkyl.

67. (New) A packaged pharmaceutical composition according to claim 48, wherein the compound is selected from:

1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

(1*S*, 2*S*)-1-(4-bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl)methylpiperazine;

1*R*, 2*R*-1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Iodo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Chloro-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Phenyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperazine;

1-(4-Bromo-3-methoxyphenyl)-4-[*trans*-2-(3-methoxyphenyl)cyclopropyl]

methylpiperazine;

1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[4-chlorophenyl] cyclopropyl) methylpiperazine;

1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[2-methylphenyl] cyclopropyl)methylpiperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-[4-methoxyphenyl]
 cyclopropyl)methylpiperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Iodo-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Chloro-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Methyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Trifluormethyl-3-methoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Bromo-3-ethoxyphenyl)-4-(*trans*-2-phenylcyclopropyl) methylpiperidine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-phenyl]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2-methylphenyl}]propen-2-yl)piperazine;
 1-(3-Methoxyphenyl)-4-([3-phenyl]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-methylphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2-methoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-chlorophenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3-ethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,3-dimethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{3,4-dimethoxyphenyl}]propen-2-yl)piperazine;
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,5-dimethoxyphenyl}]propen-2-yl)piperazine; and
 1-(4-Bromo-3-methoxyphenyl)-4-([3-{2,4-dimethoxyphenyl}]propen-2-yl)piperazine.